Dyno Therapeutics focuses on improving gene therapy by creating Adeno-associated virus (AAV) vectors, which are essential for delivering genetic material into cells. Their technology utilizes Artificial Intelligence to design and optimize these vectors, enhancing the effectiveness of gene therapies. Unlike many competitors, Dyno's unique approach combines AI with biotechnology, allowing for tailored solutions that meet the specific needs of pharmaceutical and biotech companies. Their goal is to collaborate with these companies to develop better gene therapies for various diseases, including those affecting muscles, the central nervous system, liver, and eyes.

Polaris Partners

Charles River Ventures

Lux Capital

Obvious Ventures

Casdin Capital

Andreessen Horowitz

KdT Ventures

AI & Machine Learning

Biotechnology

Healthcare

Dyno Therapeutics

Last year, Dyno introduced Low-shot Efficient Accelerated Performance (LEAP[SM]) to efficiently generate capsid sequences with improved performance beyond any of the capsids in the training data.

JPM: Roche Licenses Dyno Therapeutics' AAV Vector for Neurological Gene Therapy

Form Bio, a provider of computational life sciences technology and an offshoot of George Church’s Colossal Biosciences, announced the launch of FORMsight AI, an AI-based solution for predicting and optimizing manufacturing outputs of cell and gene therapy constructs.

Live from Los Angeles, ASGCT Goes Prime Time

Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids That can expand the potential of genetic medicine, today announced a Dyno Scientific Symposium and the presentation of four research abstracts at the upcoming 26 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-20, 2023 in Los Angeles, Calif.

Dyno Therapeutics Presents New Data on AAV Capsids Optimized with Potential for Transformative Therapeutic Deployment at the 2023 Annual Conference of the American Society of Gene & Cell Therapy. | Domain Blogger

Another investment came from Astellas investing in Dyno Therapeutics to develop adeno-associated virus (AAV) vectors for gene therapies.

Astellas is developing adeno-associated virus vectors for gene therapies

Astellas Pharma and Dyno Therapeutics have announced an option and license agreement to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno’s CapsidMap ™ platform.

Dyno Tx is developing CapsidMap  platform

After a major spike during the COVID-19 pandemic years, cell and gene therapy investment has since slowed down considerably. The figures now look pale in comparison to the $19.9 billion made in 2020 and the $22.7 billion made in 2021, with levels falling to $12.6 billion in 2022 and $11.7 billion in 2023. This has led to many gene therapy companies in particular needing to cut programs or lay off workers to save money. In this article, we explore what is behind the investment slowdown and detail the unfortunate consequences of this.Table of contentsWhat’s behind the dip in investment in the gene therapy sector?As promising as gene therapies are, one of the main issues for investors is that these types of treatments come with a lot of risk and, even if they are successful, it takes a long time for them to produce monetary rewards, as they require much longer than other types of therapies to advance through the clinic before eventually reaching the market.“We’re largely seeing investments shifting to things that are de-risked,” said Jon Norris, managing director at HSBC Innovation Banking, in a statement to Biopharma Dive. “Cell and gene therapy is becoming an area we know better, because there are products that have advanced through development, but it still doesn’t compare to the number of approvals and drugs commercially available in small molecules or biologics.”Manufacturing bottlenecks are also a major factor putting off investors. Manufacturing gene therapies generally involves a long process that can take weeks to complete, as a patient’s cells are collected, multiplied, and modified in a laboratory

Gene Editing Sector Investment Struggles: What’S Driving The Slowdown?

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, today hosted a Scientific Symposium at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held in Baltimore, MD.The Scientific Symposium showcased Dyno’s approach to applying artificial intelligence to engineering novel adeno-associated virus (AAV) capsids for optimized in vivo delivery. The Symposium, titled “AAV Capsid Design in the Era of AI,” covered Dyno’s approach to solving one of the most difficult challenges of gene therapy: safely and efficiently delivering therapeutic DNA to target organs within a patient’s body.“The present AI revolution in biotech was prefaced by decades of exponential change in the tech industry which catalyzed the personal computer revolution by putting a computer on every desk in every home, then into every pocket and on every wrist. Now the convergence of exponential change in AI, genome sequencing, and DNA synthesis technologies is driving a similar trend, this time with respect to the cost of in vivo gene delivery,” said Eric Kelsic, Ph.D., Founder and Chief Executive Officer of Dyno Therapeutics.“Today gene therapies can cost several millions of dollars per dose,” Kelsic continued. “Dyno is committed to reducing the cost of delivering therapeutic DNA down to zero, which will be key to making the next generation of transformative gene therapies even more affordable. Historical trends suggest that dramatic cost reductions will actually grow the overall gene therapy market, supporting a robust ecosystem of gene therapy developers and eventually enabling billions of patients to benefit from life-changing gene therapies."Using generative AI, Dyno recently increased the efficiency of capsid-mediated in vivo DNA delivery in the eye by 80-fold with the Dyno eCap™ 1 capsid, and to the brain by 100-fold with the Dyno bCap™ 1 capsid. Building on these initial successes, Kelsic shared how Dyno’s AI-powered methods achieved two breakthroughs, in Low-Shot Efficient Accelerated Performance (LEAP), and in the design of synthetic capsid serotypes:Capsids designed with LEAP dramatically outperformed capsids designed by humans without AI-assistance, improving in vivo delivery efficiency and potentially enabling lower manufacturing costs: Dyno developed LEAP technology to efficiently generate capsid sequences with enhanced performance beyond any of the capsids in the training data

Dyno Therapeutics Unveils Path To Exponentially Reducing The Cost Of In Vivo Gene Delivery At The 2024 American Society Of Gene  Cell Therapy (Asgct) Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design. Everything life does is controlled by biological sequences: DNA, RNA, and proteins. The capacity to design these sequences can drastically improve outcomes in healthcare and technology. Over the past decade, Dyno has pioneered an AI-powered approach to sequence design, creating some of the first in vivo-validated biologics using generative AI. Recently, Dyno’s proprietary generative AI methods yielded optimized capsid products that allow enhanced in vivo delivery of genetic therapies for Dyno’s partners, including the Dyno eCap™ 1 capsid in the eye and the Dyno bCap™ 1 capsid in the brain. Both have been validated through in vivo studies

Dyno Therapeutics To Accelerate Design Of High-Performance Biological Sequences Using Nvidia Ai

Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno's field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, today announced a Scientific Symposium and the presentation of three research abstracts, including one oral presentation, at the upcoming 27th Annual Congress of the American Society of Gene & Cell Therapy (ASGCT) being held May 7-11th, 2024 in Baltimore, Maryland. That same week Dyno Therapeutics will also be giving two talks on the theme of Machine Learning at SynBioBeta’s Global Synthetic Biology Conference held from May 6-9th, 2024 in San Jose, California.From its inception, Dyno Therapeutics has been a leader in applying generative AI to advance the frontiers of AAV engineering. Through its AI-powered platform, the company has achieved improved gene delivery to a broad array of gene therapy targets, developing capsids to target the eye, muscle and brain. The company’s presence at both the ASGCT and SynBioBeta conferences will highlight recent successes from applying machine learning to capsid design, and explore what these applications mean for gene therapy in an era of rapid AI development.Dyno’s ASGCT Scientific Symposium will showcase how artificial intelligence enables the design of novel capsids optimized across multiple in vivo delivery properties, and furthermore makes it possible to create synthetic capsids with high-edit distances from natural serotypes, thereby potentially allowing more patients to benefit from gene therapies. At SynBioBeta, Dyno engineers will delve into the reality of ML-driven approaches, highlighting both the promise and challenges that arise when solving real-world problems like in vivo delivery for gene therapies via capsid design.ASGCT Dyno Scientific SymposiumTitle: “ AAV Capsid Design in the Era of Artificial Intelligence”Presenter: Eric Kelsic, Ph.D., Founder and CEO, Dyno TherapeuticsDate and Time: May 9th, 2024 12:15 - 13:15 EDTLocation: Baltimore Convention Center, Room 307-310ASGCT Research AbstractsOral Presentation: Applying Artificial Intelligence to Multi-Property Optimization of AAV Capsids for Neuronal Gene DeliveryDate and Time: May 10th, 2024 17:00 - 17:15 EDTLocation: Baltimore Convention Center, Ballroom 4Abstract: #301Poster Presentation: Non-Human Primate Evaluation of an Engineered AAV Capsid for Retinal Cell-Specific and Biofactory-Based Ocular Gene TherapiesDate and Time: May 8th, 2024 12:00 - 19:00 EDTAbstract: #516Poster Presentation: Expanding the Serotype Frontier: Design of Synthetic AAV Capsids with Artificial IntelligenceDate and Time: May 10th, 2024 12:00 - 19:00 EDTAbstract: #1465SynBioBeta Global Synthetic Biology ConferenceOral Presentation: AI-Designed Capsids: Powering a New Age of Genetic MedicineDate and Time: May 8th, 2024 11:00 - 11:45 PDTLocation: San Jose Convention Center, Main Stage - Grand Ballroom 220ALunch & Learn: Generative AI is Not Enough: Bridging In-Silico to Impact—Where Hype Faces RealityDate and Time: May 9th, 2024 12:15 - 13:00 PDTLocation: San Jose Convention Center, Meeting Room 212BAbout Dyno TherapeuticsDyno Therapeutics is solving the in vivo gene delivery challenge while partnering with gene therapy developers towards maximizing patient impact. Dyno’s platform combines AI with high-throughput experimentation to accelerate the design of AAV capsids with properties that significantly outperform current in vivo gene delivery vectors, with the goal of expanding the range of diseases treatable with genetic medicines

Dyno Therapeutics To Present On Breakthroughs In Ai Methods For Aav Capsid Design At Asgct Annual Congress And Synbiobeta Global Synthetic Biology Conference

Develops AI-optimized AAV vectors for gene therapy

Dyno Therapeutics

Develops AI-optimized AAV vectors for gene therapy

Dyno Therapeutics

Develops AI-optimized AAV vectors for gene therapy

About

Simplify's Take

What believers are saying

What critics are saying

What makes Dyno Therapeutics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Dyno Therapeutics is Hiring for 0 Jobs on Simplify!